Phase II/III clinical trial - Sarcomes

SEAL (KCP-330-020)
Sarcomes
Ouvert depuis le: 12.04.2020
Site: Paris
Public cible
Adulte
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Description de l'essai

This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 279 total patients will be randomized to study treatment (selinexor or placebo).